These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
227 related articles for article (PubMed ID: 33059476)
1. No additive effect of combining sumatriptan and olcegepant in the GTN mouse model of migraine. Ernstsen C; Christensen SL; Olesen J; Kristensen DM Cephalalgia; 2021 Mar; 41(3):329-339. PubMed ID: 33059476 [TBL] [Abstract][Full Text] [Related]
2. No central action of CGRP antagonising drugs in the GTN mouse model of migraine. Christensen SL; Ernstsen C; Olesen J; Kristensen DM Cephalalgia; 2020 Aug; 40(9):924-934. PubMed ID: 32223300 [TBL] [Abstract][Full Text] [Related]
6. Cortical spreading depolarisation-induced facial hyperalgesia, photophobia and hypomotility are ameliorated by sumatriptan and olcegepant. Tang C; Unekawa M; Kitagawa S; Takizawa T; Kayama Y; Nakahara J; Shibata M Sci Rep; 2020 Jul; 10(1):11408. PubMed ID: 32651400 [TBL] [Abstract][Full Text] [Related]
7. Pharmacology of erenumab in human isolated coronary and meningeal arteries: Additional effect of gepants on top of a maximum effect of erenumab. de Vries T; Rubio-Beltrán E; van den Bogaerdt A; Dammers R; Danser AHJ; Snellman J; Bussiere J; MaassenVanDenBrink A Br J Pharmacol; 2024 Jun; 181(12):1720-1733. PubMed ID: 38320397 [TBL] [Abstract][Full Text] [Related]
9. Targeting CGRP via receptor antagonism and antibody neutralisation in two distinct rodent models of migraine-like pain. Christensen SL; Petersen S; Kristensen DM; Olesen J; Munro G Cephalalgia; 2019 Dec; 39(14):1827-1837. PubMed ID: 31288556 [TBL] [Abstract][Full Text] [Related]
10. A c-Fos activation map in nitroglycerin/levcromakalim-induced models of migraine. Wu S; Ren X; Zhu C; Wang W; Zhang K; Li Z; Liu X; Wang Y J Headache Pain; 2022 Sep; 23(1):128. PubMed ID: 36180824 [TBL] [Abstract][Full Text] [Related]
11. Is there an inherent limit to the efficacy of calcitonin gene-related peptide receptor antagonists in the acute treatment of migraine? A comment. Tfelt-Hansen PC J Headache Pain; 2009 Dec; 10(6):389-91. PubMed ID: 19779958 [TBL] [Abstract][Full Text] [Related]
12. CGRP receptor antagonists: an expanding drug class for acute migraine? Negro A; Lionetto L; Simmaco M; Martelletti P Expert Opin Investig Drugs; 2012 Jun; 21(6):807-18. PubMed ID: 22512641 [TBL] [Abstract][Full Text] [Related]
13. Pharmacological synergy: the next frontier on therapeutic advancement for migraine. Blumenfeld A; Gennings C; Cady R Headache; 2012 Apr; 52(4):636-47. PubMed ID: 22221151 [TBL] [Abstract][Full Text] [Related]
14. Evaluation of the Pharmacokinetic Interaction of Ubrogepant Coadministered With Sumatriptan and of the Safety of Ubrogepant With Triptans. Jakate A; Boinpally R; Butler M; Lu K; McGeeney D; Periclou A Headache; 2020 Jul; 60(7):1340-1350. PubMed ID: 32573795 [TBL] [Abstract][Full Text] [Related]
15. Recurrent administration of the nitric oxide donor, isosorbide dinitrate, induces a persistent cephalic cutaneous hypersensitivity: A model for migraine progression. Dallel R; Descheemaeker A; Luccarini P Cephalalgia; 2018 Apr; 38(4):776-785. PubMed ID: 28565942 [TBL] [Abstract][Full Text] [Related]
16. Antagonism of CGRP Receptor: Central and Peripheral Mechanisms and Mediators in an Animal Model of Chronic Migraine. Greco R; Demartini C; Francavilla M; Zanaboni AM; Tassorelli C Cells; 2022 Sep; 11(19):. PubMed ID: 36231054 [TBL] [Abstract][Full Text] [Related]
18. PACAP signaling is not involved in GTN- and levcromakalim-induced hypersensitivity in mouse models of migraine. Guo S; Ernstsen C; Hay-Schmidt A; Kristensen DM; Ashina M; Olesen J; Christensen SL J Headache Pain; 2022 Dec; 23(1):155. PubMed ID: 36471250 [TBL] [Abstract][Full Text] [Related]
19. History and Review of anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: From Translational Research to Treatment. Tepper SJ Headache; 2018 Nov; 58 Suppl 3():238-275. PubMed ID: 30242830 [TBL] [Abstract][Full Text] [Related]
20. Place of next generation acute migraine specific treatments among triptans, non-responders and contraindications to triptans and possible combination therapies. de Boer I; Verhagen IE; Souza MNP; Ashina M Cephalalgia; 2023 Feb; 43(2):3331024221143773. PubMed ID: 36739516 [No Abstract] [Full Text] [Related] [Next] [New Search]